# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $11 price ...
HC Wainwright & Co. analyst Andres Maldonado maintains Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $11 price t...
Ikena Oncology (NASDAQ:IKNA) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43...
Ikena Oncology optimizes resources for targeted oncology programs IK-930 & IK-595. Clinical updates expected H2 2024. Workf...
Wedbush analyst David Nierengarten reiterates Ikena Oncology (NASDAQ:IKNA) with a Outperform and maintains $8 price target.
HC Wainwright & Co. analyst Andres Maldonado reiterates Ikena Oncology (NASDAQ:IKNA) with a Buy and maintains $11 price ...